Volume 25, Number 11—November 2019
CME ACTIVITY - Research
Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease
Table 1
Demographics and clinical characteristics of patients in study of treatments for West Nile virus central nervous system disease, by treatment arm*
Characteristic | Omr-IgG-am, n = 37 | Polygam, n = 12 | Normal saline, n = 13 | Total, n = 62 |
---|---|---|---|---|
Race | ||||
Caucasian/not Hispanic | 24 (64.9) | 10 (83.3) | 11 (84.6) | 45 (72.6) |
Black/not Hispanic | 2 (5.4) | 0 | 1 (7.7) | 3 (4.8) |
Hispanic | 8 (21.6) | 1 (8.3) | 1 (7.7) | 10 (16.1) |
Other |
3 (8.1) |
1 (8.3) |
0 (0) |
4 (6.5) |
Sex | ||||
M | 25 (67.6) | 7 (58.3) | 9 (69.2) | 41 (66.1) |
F |
12 (32.4) |
5 (41.7) |
4 (30.8) |
21 (33.9) |
Age, y, mean ± SE |
56.2 ± 2.2 |
54.0 ± 4.1 |
58.4 ± 4.8 |
56.2 ± 1.8 |
Cerebrospinal fluid | ||||
Leukocytes, cells/µL, mean ± SE (median) | 207.7 ± 40.3 (124) | 187.4 ± 105.5 (58) | 146.6 ± 85.8 (37) | 192.3 ± 35.3 (95.5) |
% Lymphocytes, mean ± SE (median) |
53.9 ± 5.0 (52.5) |
39.3 ± 10.0 (36.5) |
50.2 ± 11.6 (34) |
50.1 ± 4.3 (43) |
Time from admission to drug infusion, d,
mean ± SE (median) |
2.9 ± 0.5 (2) |
2.8 ± 0.5 (2.5) |
2.0 ± 0.4 (2) |
2.7 ± 0.3 (2) |
Disease group and risk factors | ||||
With encephalitis/myelitis | 25 (64.7) | 9 (75.0) | 11 (84.6) | 44 (71.0) |
Without encephalitis/myelitis | 12 (32.4) | 3 (25.0) | 2 (15.4) | 17 (27.4) |
Hematologic malignancy | 1 (8.3) | 0 | 0 | 1 (5.9) |
Diabetes mellitus | 2 (16.7) | 0 | 0 | 2 (11.8) |
Bone marrow transplant |
1 (8.3) |
0 |
0 |
1 (5.9) |
Immunosuppressive medications | 1 (8.3) | 0 | 0 | 1 (5.9) |
*Values are no. (%) patients except as indicated. In comparing Omr-IgG-am with Polygam and Omr-IgG-am with normal saline, no significant differences were identified for characteristics listed in this table (all p values >0.05). Denominators vary according to the number of evaluable patients or assessments.
Page created: October 15, 2019
Page updated: October 15, 2019
Page reviewed: October 15, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.